Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA06 in Relapsed/Refractory Acute Myeloid Leukemia
NCT05731219Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA06 in acute myeloid leukemia (AML), sponsored by PersonGen BioTherapeutics. Primary endpoint: Safety and Tolerability at 2 years. Started Sep 2022; status: recruiting.
02
Drugs
UTAA06
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05731219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731219.